Dec 2 The European Medicines Agency warned on
Friday that some of the most successful hepatitis C treatments
on the market could reactivate hepatitis B in patients.
The agency recommended that patients be screened to ensure
they are not infected with both kinds of virus before being
treated for hepatitis C.
The Pharmacovigilance Risk Assessment Committee's warning
was against a class of treatment called direct acting
anti-virals, which include Gilead Sciences Inc's
Sovaldi, AbbVie Inc's Exviera and Viekirax, Johnson &
Johnson's Olysio and Bristol-Myers Squibb's
(Reporting by Vidya L Nathan in Bengaluru; Editing by Savio